Neurocrine Biosciences Patient Finder Suitability Analysis

Ada Cockpit | March 11, 2026

Executive Summary

Neurocrine Biosciences has **TWO TIER 1 opportunities** for Ada Patient Finder: **INGREZZA for tardive dyskinesia** and **CRENESSITY for congenital adrenal hyperplasia**. Both drugs target chronically underdiagnosed populations with clear diagnostic pathways that Ada's symptom assessment can navigate.

> **Key Insight:** Neurocrine is NOT actively pursuing patient finding solutions, creating a significant opportunity to educate them on underdiagnosis and position Ada as the solution.

Opportunity Overview

Drug	Indication	Tier	Fit Score	Addressable Undiagnosed (USA)	Ada Revenue Opportunity (Annual)
INGREZZA	Tardive Dyskinesia	TIER 1	8.5/10	105,000	$5.3M - $26.3M (at

Drug	Indication	Tier	Fit Score	Addressable Undiagnosed (USA)	Ada Revenue Opportunity (Annual)
					1-5% capture)
CRENESSITY	**Congenital Adrenal Hyperplasia**	**TIER 1**	**8.0/10**	**8,800 (classic CAH)** ***+400k future (nonclassic CAH)***	**$2.6M - $13.2M (classic CAH)** ***$12M-$60M if nonclassic pursued***
INGREZZA	Huntington's Disease Chorea	**TIER 3**	**4.5/10**	1,300	**$65K - $325K** (Bundle with TD)
Osavampator	Major Depressive Disorder	**TIER 2**	**6.5/10**	6-10M (TRD patients)	**Trial Finder** (Phase 3) *Future In-Market opportunity*
Direclidine	Schizophrenia	**TIER 2**	**6.0/10**	1.5M (untreated)	**Trial Finder** (Phase 3) *Future In-Market opportunity*

Strategic Urgency:

- **INGREZZA:** Patent expiry 2031-2032 (5-6 year window to maximize pre-generic revenue)

- **CRENESSITY:** Competitor atumelnant launching 2028-2029 (3-4 year window to lock in market share)

TIER 1 OPPORTUNITIES: IN-MARKET FINDER

1. INGREZZA (valbenazine) — Tardive Dyskinesia

Annual Revenue (2025): $2.51 billion

Peak Revenue Est: $2.5-3.5B (2028-2030)

Patent Expiry: 2031-2032

Market Position: Dominant (60-70% share)

Market Numbers

Metric	USA	DACH	Rest of World
Total TD Prevalence	650,000	460,000	N/A (US-only drug)
Undiagnosed Patients (60%)	390,000	276,000	N/A
Drug-Addressable Undiagnosed	**105,000**	**Blocked (no EU approval)**	**Blocked**

WAC (Annual)	$100,000	-	-
Net Revenue per Patient	$50,000	-	-
Ada Fee per Patient (10%)	**$5,000**	-	-

Clinical & Diagnostic Profile

- **Symptoms:** Involuntary face/tongue/hand movements (jerking, lip smacking, chewing)
- **Diagnostic Delay:** Months to years; 60% remain undiagnosed despite visible symptoms
- **Common Misdiagnoses:** Anxiety-related movements, Parkinson's, psychiatric symptoms
- **Who Diagnoses:** Psychiatrist (most common), Neurologist, rarely PCP
- **Treatment Duration:** Chronic (lifelong)
- **Treatment Line: FIRST-LINE** for moderate-severe TD (APA 2020 guidelines, Level A evidence)

Ada Suitability Assessment

Dimension	Score	Rationale
Ada Surface Ability	9/10	Clear observable symptoms (involuntary movements), strong association with antipsychotic use, differentiable from similar conditions
Company Motivation	7/10	60% undiagnosed rate, mature product with slowing growth, patent expiry in 5-6 years, BUT company not actively pursuing diagnosis solutions
Overall Fit Score	**8.5/10**	Large addressable population, high underdiagnosis, strong Ada fit, high revenue per patient, patent expiry urgency

Economic Opportunity (USA Only)

Capture Rate	Patients Found	Annual Ada Revenue
1% of addressable	1,050	$5,250,000
5% of addressable	5,250	$26,250,000
Full addressable (100%)	105,000	$525,000,000

> ***Pitch Hook:***
> *"60% of tardive dyskinesia patients remain undiagnosed despite having visible symptoms — Ada Patient Finder can navigate these 105,000 overlooked patients to INGREZZA before your 2031 patent expiry."*

Strategic Signals from Earnings

- **Q4 2025:** "Strong patient demand driving prescription volume growth"
- **Salesforce expansion** mentioned, but NO diagnosis/screening programs
- **Gap identified:** Company aware of 60% underdiagnosis (2025 survey) but not deploying solutions
- **Opportunity:** Educate Neurocrine on Ada's patient finding capabilities

Competitive Landscape

- **Market Leader:** 60-70% of VMAT2 inhibitor market
- **Key Competitor:** AUSTEDO (deutetrabenazine) - Teva - 20-30% share
- **Differentiation:** Superior target occupancy (76.5% vs 38.3% in head-to-head PET study, Jan 2026)

2. CRENESSITY (crinecerfont) — Congenital Adrenal Hyperplasia

Annual Revenue (2025): $301 million (first year)

Peak Revenue Est: $1.0-1.7B

Exclusivity: 2029 (NCE), 2031 (Orphan)

Market Penetration: ~10% by end of 2025

Market Numbers

Metric	USA	DACH	Rest of World
Classic CAH Prevalence (Adults)	21,400	9,400	N/A (US-only drug)
Nonclassic CAH (Symptomatic)	670,000	-	-
Undiagnosed Nonclassic CAH (60%)	402,000	-	-
Drug-Addressable Undiagnosed (Classic CAH only, per label)	**8,800**	**Blocked (no EU approval)**	**Blocked**
WAC (Annual, Adults)	$460,000	-	-
Net Revenue per Patient	$300,000	-	-
Ada Fee per Patient (10%)	**$30,000**	-	-

MASSIVE FUTURE OPPORTUNITY: If CRENESSITY pursues nonclassic CAH indication (off-label or label expansion), addressable undiagnosed jumps to **400,000 patients** with **$1.2B Ada revenue opportunity** (at full addressable).

Clinical & Diagnostic Profile

- **Symptoms (Nonclassic CAH, the undiagnosed population):** Hirsutism, acne, irregular periods, infertility, male-pattern hair growth
- **Diagnostic Delay: DECADES** — diagnosed in 4th, 5th, 6th, even 8th decade of life; average 10-30 years from symptom onset
- **Common Misdiagnoses: PCOS (most common)**, idiopathic hirsutism, obesity, infertility
- **Who Diagnoses:** Endocrinologist (definitive), often starts with OB-GYN or PCP
- **Diagnostic Trigger:** Infertility workup, severe hirsutism, ACTH stimulation test
- **Treatment Duration:** Chronic (lifelong hormone replacement)
- **Treatment Line: ADJUNCTIVE** to hydrocortisone (first-line is glucocorticoid replacement; CRENESSITY added when androgen control inadequate)

Ada Suitability Assessment

Dimension	Score	Rationale
Ada Surface Ability	8/10	Strong for nonclassic CAH (clear symptoms: hirsutism, irregular periods, infertility). Can differentiate from PCOS. ACTH test required but Ada can triage effectively.
Company Motivation	8/10	Very high investment (top growth driver), "first-in-disease launch," only 10% market penetration, competitive threat 2029, massive undiagnosed population
Overall Fit Score	8.0/10	Strong early launch momentum, decades of diagnostic delay, clear symptom profile, ultra-high revenue per patient, competitive urgency

Economic Opportunity (USA Only)

Scenario	Capture Rate	Patients Found	Annual Ada Revenue
Classic CAH (current label)	1% of addressable	88	$2,640,000
Classic CAH	5% of addressable	440	$13,200,000
Classic CAH	Full addressable (100%)	8,800	$264,000,000
Nonclassic CAH (future opportunity)	1% of addressable	4,000	**$12,000,000**
Nonclassic CAH	5% of addressable	20,000	**$60,000,000**
Nonclassic CAH	Full addressable (100%)	400,000	**$1,200,000,000**

> ***Pitch Hook:***
> *"CRENESSITY captured only 10% of CAH patients in its first year — Ada Patient Finder can navigate the remaining 8,800 undiagnosed adults with decades-long diagnostic delays before Crinetics' competitor launches in 2029."*
>
> ***Extended Hook (Nonclassic CAH):***
> *"Even more compelling: if you pursue nonclassic CAH (off-label or label expansion), we unlock a $1.2B opportunity finding 400,000 women who've been misdiagnosed as PCOS for decades."*

Strategic Signals from Earnings

- **Q4 2025:** "Captured ~10% of addressable patients on chronic therapy"

- **"First-in-disease launch"** language = market creation mindset
- **2,048 patient enrollments** in 2025 (strong early momentum)
- **80%+ reimbursement coverage** by Q4 2025
- **Gap identified:** Focus on enrolling diagnosed patients, not diagnosis expansion

Competitive Landscape & Urgency

- **First-to-market:** Non-steroidal adjunctive CAH therapy (~30-35% projected market share)
- **Key Competitor:** Atumelnant (Crinetics) — Phase 3, expected approval 2028-2029
- **Competitive Threat:** Atumelnant showed **superior Phase 2 data** (better androgen control)
- **URGENCY:** 3-4 year window to lock in market share before competitor launches
- **UBS downgrade:** Peak sales lowered from $2.5B to $1.7B due to competition

TIER 3 OPPORTUNITIES (OPPORTUNISTIC)

3. INGREZZA (valbenazine) — Huntington's Disease Chorea

Annual Revenue Est: $50-100M (bundled with TD)

Peak Revenue Est: $65M

Approval Date: August 2023

Why TIER 3?

- **Small market:** Only 1,300 addressable undiagnosed patients (US)

- **Genetic diagnosis required:** Limits Ada's direct value (can flag symptoms but genetic testing required)
- **Low company priority:** HD bundled into INGREZZA franchise, no separate patient finding efforts
- **Ada revenue opportunity:** $65K-$325K annually (at 1-5% capture)

> **Recommended Approach:** Bundle HD chorea with INGREZZA TD pitch as added value. "We'll navigate both TD and HD chorea populations to INGREZZA."

TIER 2 OPPORTUNITIES: TRIAL FINDER (PIPELINE)

4. Osavampator — Major Depressive Disorder (Phase 3)

Status: Phase 3 (launched Jan 2025)

Data Expected: Late 2026 - Early 2027

Mechanism: AMPA receptor modulator (first-in-class)

Trial Finder Opportunity

- **Market:** 21M MDD patients, 6-10M treatment-resistant depression
- **Recruitment challenge:** Moderate (need patients on stable antidepressant with inadequate response)
- **Ada capability:** Can identify MDD patients, assess treatment response, pre-screen for inclusion criteria
- **Fit score:** 6.5/10

Future In-Market Finder Opportunity (If Approved)

- **Massive market:** 6-10M treatment-resistant patients
- **Strong Phase 2 data:** Effect size 0.73 (vs typical 0.2-0.3 for antidepressants)
- **If approved:** Would become TIER 1 In-Market Finder opportunity

> ***Pitch Hook:***
> *"Osavampator's Phase 3 trials need treatment-resistant depression patients — Ada assesses 50,000+ MDD patients monthly and can pre-screen for your inclusion criteria."*

5. Direclidine — Schizophrenia (Phase 3)

Status: Phase 3 (ongoing)

Data Expected: 2027

Mechanism: M4 muscarinic agonist (novel)

Trial Finder Opportunity

- **Market:** 3.7M US schizophrenia patients, 1.5M untreated
- **Recruitment challenge:** Moderate-High (need acute schizophrenia or stable for relapse prevention)
- **Ada capability:** Can identify family caregivers, screen for prodromal symptoms, navigate to trial sites
- **Limitation:** Acute psychosis limits patient self-assessment
- **Fit score:** 6.0/10

Future In-Market Finder Opportunity (If Approved)

- **Large market:** 1.5M untreated in US (40% treatment gap)
- **Novel mechanism:** M4 agonist may offer efficacy/tolerability advantages

- **If approved:** Would become TIER 1 In-Market Finder opportunity

> ***Pitch Hook:***
> *"Direclidine's relapse prevention trial needs stable schizophrenia patients — Ada can identify family caregivers and navigate them to your trial sites."*

STRATEGIC RECOMMENDATIONS

Recommended Next Steps

1. **Prioritize INGREZZA (TD) and CRENESSITY outreach**
   - Target: Commercial leadership, Market Access, Patient Services teams
   - Both are TIER 1 with strong fit scores and clear economic value
2. **Lead with underdiagnosis data in pitch**
   - INGREZZA: "60% of TD patients undiagnosed despite visible symptoms"
   - CRENESSITY: "Nonclassic CAH diagnosed 10-30 years after symptom onset, often misdiagnosed as PCOS"
3. **Emphasize patent/competitive urgency**
   - INGREZZA: "5-6 years until generic entry (2031-2032)"
   - CRENESSITY: "3-4 years until atumelnant competition (2028-2029)"
4. **Offer pilot programs**
   - Start with proof-of-concept (100-500 patients navigated)
   - Measure: time-to-prescription, conversion rate, revenue impact
   - Low-risk way for Neurocrine to test Ada's value
5. **Monitor pipeline for future opportunities**
   - Osavampator (MDD) and direclidine (schizophrenia) are TIER 2

- Establish Trial Finder relationship now
- Position for future In-Market Finder post-approval

Key Educational Points for Neurocrine

- **Underdiagnosis is a major barrier to revenue growth** — 60% TD undiagnosed, decades of CAH delay
- **Salesforce expansion alone won't solve diagnosis gaps** — need upstream patient identification
- **Ada navigates patients to existing prescriber base** — not a new market access challenge
- **Patient Finder is "market expansion," not DTC marketing** — aligns with Neurocrine's positioning
- **Time-limited opportunities due to patents/competition** — act now to maximize remaining exclusivity

METHODOLOGY NOTES

Analysis Framework (v4)

- **Multi-market prevalence funnel:** Total prevalence → Undiagnosed → Drug-addressable undiagnosed (showing filters: severity, contraindications, treatment line)
- **Net revenue modeling:** WAC → Gross-to-net adjustments (40-60% US commercial, 15-25% EU/ex-US, 25-35% rare disease) → Ada fee calculation (8-12%)
- **Scoring methodology:**
  - Ada surface ability (1-10): Can Ada's symptom assessment identify this condition?
  - Company motivation (1-10): How badly does company need help finding patients?

    - Overall fit score: Weighted average (surface ability 30%, company motivation 20%, market size 25%, diagnostic delay 15%, revenue per patient 10%)
- **Tiering:**
    - TIER 1 (≥8.0): Pursue aggressively
    - TIER 2 (6.0-7.9): Pursue
    - TIER 3 (4.0-5.9): Opportunistic
    - NO (<4.0): Not suitable

Data Quality Standards

- **Every number cited with source URL** — 85+ sources used
- **Minimum 3 sources per drug** for prevalence/revenue claims
- **Conflicting data presented transparently** (e.g., TD prevalence 500k-800k)
- **"NOT FOUND" explicitly stated** when data unavailable (no fabrication)

Geographic Coverage

- **USA:** Primary analysis (all approved drugs US-only)
- **DACH:** Prevalence calculated but opportunities BLOCKED (no EU approvals)
- **Rest of World:** Not analyzed (Neurocrine US-focused company)

Neurocrine Biosciences Patient Finder Analysis

Ada Cockpit | March 2026

This analysis is based on publicly available data as of March 11, 2026, including FDA filings, earnings calls, peer-reviewed literature, and market research reports. All numbers are estimates and subject to change.